Board of directors

David Agus, M.D., Navigenics Co-founder

Dr. David Agus is a Professor of Medicine at the University of Southern California and Director of the USC Center for Applied Molecular Medicine and the USC Westside Prostate Cancer Center. In addition to co-founding Navigenics, Dr. Agus also founded Oncology.com, the largest cancer internet resource/community. More

Brook Byers (observer), Partner, Kleiner Perkins Caufield & Byers

Brook Byers has been a venture capital investor since 1972. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. He is currently on the Board of Directors of ten companies, most recently joining CardioDX, Genomic Health Incorporated and Pacific Biosciences. More

Michael J. Critelli (observer)

At Pitney Bowes Inc., Mr. Critelli served as CEO for 11 years and Chairman for 12 years. He currently serves as the Chairman of the Board for the Dossia Foundation. He also serves on the Board of Directors for both Wyeth and the Eaton Corporation, as well as the Partnership for Prevention and the RAND Health Advisors boards and the Institute of Medicine’s Roundtable for Evidence-Based Medicine. More

Mark Kvamme (observer), Partner, Sequoia Capital

Mark Kvamme focuses on investments in software and services. Prior to joining Sequoia Capital in 1999, he was chairman of USWeb/CKS. More

Jonathan “Jack” T. Lord, M.D.

Dr. Lord was Chief Innovation Officer for Kentucky-based Humana, Inc., where he led the development of new products and services to fundamentally transform the healthcare system and support personal health needs. More

Dana G. Mead, Jr., Partner, Kleiner Perkins Caufield & Byers

Dana G. Mead has focused on identifying new medical technologies, developing new markets and therapies and building world-class management teams. Prior to joining KPCB, Mr. Mead was president of Guidant Vascular Intervention. More

Sue Siegel, Partner, MDV-Mohr Davidow Ventures

Sue Siegel has spent more than two decades commercializing key enabling technologies in biomedical research and health care. Prior to joining MDV, Ms. Siegel was president and director of Affymetrix, a company that helped propel the expansion of the genomics field and the opportunity for personalized medicine. More

Dietrich Stephan, Ph.D., (observer), Navigenics Co-founder and Chief Science Officer

Dietrich Stephan is a human geneticist on the faculty of the Translational Genomics Research Institute and chairman of the National Institutes of Health Neuroscience Microarray Consortium. He has identified genes that predispose to disorders such as autism, exercise-induced heart attacks and sudden infant death syndrome, and contributed to understanding a multitude of common disorders such as Alzheimer's disease. More